CRIS · Curis Inc
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued.”View the 10-Q filed May 13, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.06M | $9.44M | $10.91M | $10.02M | $10.16M | $10.65M | $10.84M | $10M | $10.43M | $9.9M | $7.53M | $7.88M | $9.84M | $15M | $16.97M | $14.76M | $16M | $8.59M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $789K | — | — | — | |
| $26.16M | $28.25M | $38.56M | $39.5M | $43.28M | $34.88M | $23.07M | $22.3M | $24.41M | $45.1M | $18M | $26.7M | $13.66M | $12.93M | $15.49M | $13.69M | $11.37M | $9.93M | |
| $15.13M | $14.05M | $16.79M | $18.65M | $19.65M | $17.3M | $12.13M | $11.56M | $14.79M | $14.07M | $15.59M | $12.91M | $11.71M | $11.29M | $10.42M | $8.27M | $10.26M | $8.7M | |
| — | $169K | $203K | $255K | $233K | $158K | $144K | $125K | $177K | $235K | $193K | $161K | $155K | $141.52K | $126.54K | $107.4K | $686.5K | $751.21K | |
| $41.33M | $42.35M | $55.45M | $58.36M | $63.18M | $52.71M | $35.73M | $34.36M | $39.76M | $59.66M | $65.57M | $64.36M | $25.71M | $24.42M | $35.59M | $21.97M | $21.64M | $18.63M | |
| -$7.08M | -$5.71M | -$44.54M | -$48.33M | -$53.02M | -$42.07M | -$24.9M | -$24.36M | -$29.33M | -$49.76M | -$58.04M | -$56.48M | -$15.86M | -$9.42M | -$18.62M | -$7.2M | -$5.64M | -$10.04M | |
| — | -60.5% | -408.34% | -482.21% | -521.75% | -395.01% | -229.79% | -243.46% | -281.29% | -502.73% | -771.08% | -716.95% | -161.15% | -62.77% | -109.71% | -48.79% | -35.24% | -116.94% | |
| — | -$5.54M | -$44.34M | -$48.08M | -$52.79M | -$41.91M | -$24.75M | -$24.23M | -$29.16M | -$49.53M | -$57.85M | -$56.32M | -$15.71M | -$9.27M | -$18.49M | -$7.1M | -$4.95M | -$9.29M | |
| — | — | — | — | — | $0 | $0 | $791K | $3.93M | $3.97M | $2.78M | $3.33M | $3.75M | $3.84M | $204.17K | — | — | — | |
| $300K | $316K | $1.77M | $2.94M | $1.12M | $211K | $63K | $614K | $684K | $513K | $406K | $277K | $165K | $164.65K | $149.94K | $100.03K | $137.66K | $222.31K | |
| -$14.09M | -$1.87M | $1.15M | $919K | -$3.65M | -$3.37M | -$5.01M | -$7.79M | -$3.24M | -$3.56M | -$2.37M | -$2.5M | -$2.87M | -$2.91M | $2.2M | -$2.66M | $1.2M | $222.31K | |
| — | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$21.17M | -$7.58M | -$43.39M | -$47.41M | -$56.67M | -$45.44M | -$29.91M | -$32.14M | -$32.58M | -$53.32M | -$60.41M | -$58.98M | -$18.73M | -$12.32M | -$16.42M | -$9.86M | -$4.44M | -$9.82M | |
| — | -80.29% | -397.77% | -473.04% | -557.69% | -426.67% | -276.03% | -321.28% | -312.38% | -538.66% | -802.59% | -748.68% | -190.28% | -82.14% | -96.73% | -66.78% | -27.72% | -114.35% | |
| -$21.17M | -$7.58M | -$43.62M | -$47M | -$56.75M | -$45.54M | -$29.91M | -$32.14M | -$32.57M | -$53.32M | -$60.44M | -$58.94M | -$18.73M | -$12.34M | -$16.44M | -$9.87M | -$4.39M | -$9.91M | |
| USD/shares | — | -$11.60 | -$137.60 | -$179.20 | -$242.80 | $10.00 | -$12.20 | -$19.40 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$11.60 | -$137.60 | -$179.20 | -$242.80 | $10.00 | -$12.20 | -$19.40 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 658.2K | 315.31K | 264.66K | 233.48K | 4.58M | 2.43M | 1.66M | 1.66M | 1.49M | 6.64M | 6.17M | 4.3M | 4.12M | 3.95M | 3.82M | 3.75M | — |
| shares | — | 658.2K | 315.31K | 264.66K | 233.48K | 4.58M | 2.43M | 1.66M | 1.66M | 1.49M | 6.64M | 6.17M | 4.3M | 4.12M | 3.95M | 3.82M | 3.75M | — |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 304 similar-size Biotechnology companies (of 522 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $9,443,000 | $10,908,000 | $10,023,000 |
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Gross Royalty Revenue | $10,278,000 | $10,749,000 | — | — |
| Other Revenue | $0 | $1,000 | $214,000 | $0 |
| Contra Revenue | -$116,000 | -$101,000 | -$103,000 | -$414,000 |
| Royalty | — | — | $10,724,000 | $10,418,000 |